BeOne Highlights Promising Breast Cancer Data at ASCO 2025
BeOne Medicines Showcases Early Clinical Success of Two Innovative Breast Cancer Therapies at ASCO 2025 BeOne Medicines Ltd. a global biotechnology company dedicated to developing targeted therapies for cancer, announced…
Viatris Reports Positive Phase 3 LYNX-2 Results for MR-142 in Vision-Impaired Patients
Viatris Reports Positive Phase 3 Results for MR-142, Advancing a Potential First-in-Class Treatment for Night Vision Impairment in Keratorefractive Patients Viatris Inc. a global healthcare company committed to bridging access…
Jazz: Zepzelca-Tecentriq Combo Boosts Survival in First-Line SCLC Maintenance
Jazz Pharmaceuticals Reports Landmark Phase 3 Results for Zepzelca and Tecentriq Combo as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Jazz Pharmaceuticals plc has announced highly promising results…
Traditional Medicine in the Spotlight at WHA78
Traditional Medicine Moves to the Forefront at 78th World Health Assembly, Paving the Way for Global Integration Traditional medicine—long an integral part of diverse cultures and communities across the globe—commanded…
FDA Grants Priority Review to NDA for TransCon CNP
FDA Grants Priority Review to Ascendis Pharma’s NDA for TransCon® CNP in Achondroplasia Treatment Ascendis Pharma A/S a biopharmaceutical company focused on developing innovative therapies for patients with serious rare…
Protagonist & Takeda to Present Full 32-Week Phase 3 VERIFY Results on Rusfertide at ASCO
Protagonist Therapeutics and Takeda Reveal Comprehensive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera at ASCO 2025 Protagonist Therapeutics,and Takeda Pharmaceutical Company Limited have announced detailed findings from…
Sanofi to Acquire Blueprint, Boosting Rare Immunology Portfolio
Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal, Expanding Rare Immunological Disease Portfolio and Deepening Immunology Pipeline In a landmark move to expand its presence in rare immunological diseases…
Kisqali Cuts Recurrence Risk in Young Breast Cancer Patients: NATALEE Subgroup
Novartis Highlights Kisqali’s Promise in Reducing Recurrence Risk for Younger Patients with Early Breast Cancer at ASCO 2025 At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Novartis…
Camizestrant Cuts Risk of Progression or Death by 56% in ESR1-Mutant HR+ Breast Cancer
AstraZeneca’s Camizestrant Shows Landmark Efficacy in Advanced HR-Positive Breast Cancer with ESR1 Mutations in Phase III SERENA-6 Trial In a pivotal breakthrough for hormone receptor (HR)-positive, HER2-negative advanced breast cancer,…
Imfinzi Regimen Cuts Early Gastric Cancer Risk by 29% in Phase III Trial
AstraZeneca’s Imfinzi-Based Regimen Shows Significant Benefit in Early Gastric and GEJ Cancers in Phase III MATTERHORN Trial AstraZeneca has reported highly promising results from its Phase III MATTERHORN trial, showcasing…
Roche’s Fenebrutinib Sustains Disease Control in Relapsing MS for Two Years
Roche Reports Promising Two-Year Results for Fenebrutinib in Relapsing Multiple Sclerosis, Maintaining Disease Control and Halting Disability Progression Roche has released encouraging new long-term data from its investigational Bruton’s tyrosine…
Merck’s Zilovertamab Vedotin Shows Promising Results in Phase 2 DLBCL Trial
Merck’s Zilovertamab Vedotin in Combination With R-GemOx Shows Promising Efficacy in Relapsed/Refractory DLBCL Patients: Phase 2 Results from waveLINE-003 Trial Presented at ASCO 2025 Merck, known as MSD outside the…